Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara Updates Phoenix WinNonlin Validation Suite to Streamline Computer System Validation
January 27, 2015
Phoenix® WinNonlin® Validation Suite™ 4.0 can help ensure compliance, reduce total cost of ownership and improve work efficiency
PRINCETON, NJ – Jan. 27, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced the launch of Phoenix WinNonlin Validation Suite 4.0 for automatic validation of the recently released Phoenix WinNonlin version 6.4.
Regulatory authorities expect that computer systems used in the development of drug products will be validated, to ensure that the computer system complies with the user’s requirements and functions as intended. The Phoenix WinNonlin Validation Suite provides document templates for use as starting points for validation process deliverables and nearly 200 automated test scripts for testing Phoenix WinNonlin functionality. The document templates and automated scripts in Phoenix WinNonlin Validation Suite 4.0 have been updated to reflect the new functionality in Phoenix WinNonlin 6.4.
Phoenix WinNonlin is part of the premier Phoenix PK/PD software platform used by more than 5,000 biopharmaceutical companies, veterinary and academic researchers, along with the FDA, PDMA, MHRA, EMA and other regulatory authorities to analyze and report toxicokinetic (TK)/pre-clinical and clinical PK/PD data.
“Our clients who work in a regulated environment choose to utilize the Phoenix WinNonlin Validation Suite because it allows them to streamline the validation of their Phoenix WinNonlin computer system, saving time and resources, and decreasing the total cost of ownership of the Phoenix WinNonlin software, while meeting compliance expectations,” said Certara Quality Assurance Manager Debra Fontana. “Our Validation Suite solution distills the collective knowledge and experience of Certara’s pharmacokineticists, software engineers, quality engineers, quality assurance personnel, and deployment personnel into an easy-to-use tool which facilitates the efficient execution of a Phoenix WinNonlin validation project.”
Key benefits realized when using Phoenix WinNonlin Validation Suite 4.0 include:
- Meeting compliance expectations
- Ensuring that Phoenix WinNonlin functions as intended in the user's computing environment
- Reducing the need for specialized PK/PD scientist participation in the computer system validation process
- Minimizing the cost of computer system validation, by reducing the time required to complete computer system validation
To learn more about Phoenix WinNonlin Validation Suite 4.0, please visit: www.certara.com/products/pkpd/phx-wnl/phx-wnl-val/
About Certara
Certara is the global biosimulation technology-enabled drug development and drug safety consulting company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com/Phoenix
Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
teresa.bradford@certara.com
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com